Oculus Innovative
Sciences, Inc. OCLS, today announced it has enrolled the first
patients in its double-blind, randomized clinical study evaluating an advanced
Microcyn® hydrogel for management of hypertrophic or keloid scars under an
FDA-reviewed protocol. The company plans to complete its 40-patient trial and
provide top-line data by mid-2013 calendar year. The study design calls for
recruitment of up to 40 patients at four different U.S. sites, which are
Albuquerque, NM, High Point, NC, Austin, TX and College Station, TX.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in